1. Home
  2. INSM vs ETR Comparison

INSM vs ETR Comparison

Compare INSM & ETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • ETR
  • Stock Information
  • Founded
  • INSM 1988
  • ETR 1949
  • Country
  • INSM United States
  • ETR United States
  • Employees
  • INSM N/A
  • ETR N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • ETR Electric Utilities: Central
  • Sector
  • INSM Health Care
  • ETR Utilities
  • Exchange
  • INSM Nasdaq
  • ETR Nasdaq
  • Market Cap
  • INSM 41.2B
  • ETR 39.5B
  • IPO Year
  • INSM 2000
  • ETR N/A
  • Fundamental
  • Price
  • INSM $206.24
  • ETR $96.78
  • Analyst Decision
  • INSM Strong Buy
  • ETR Buy
  • Analyst Count
  • INSM 19
  • ETR 17
  • Target Price
  • INSM $173.35
  • ETR $100.38
  • AVG Volume (30 Days)
  • INSM 3.0M
  • ETR 2.6M
  • Earning Date
  • INSM 10-30-2025
  • ETR 10-29-2025
  • Dividend Yield
  • INSM N/A
  • ETR 2.65%
  • EPS Growth
  • INSM N/A
  • ETR N/A
  • EPS
  • INSM N/A
  • ETR 4.07
  • Revenue
  • INSM $447,022,000.00
  • ETR $12,730,047,000.00
  • Revenue This Year
  • INSM $40.09
  • ETR $9.49
  • Revenue Next Year
  • INSM $129.64
  • ETR $7.53
  • P/E Ratio
  • INSM N/A
  • ETR $23.74
  • Revenue Growth
  • INSM 30.34
  • ETR 7.32
  • 52 Week Low
  • INSM $60.40
  • ETR $73.15
  • 52 Week High
  • INSM $209.77
  • ETR $98.58
  • Technical
  • Relative Strength Index (RSI)
  • INSM 70.57
  • ETR 57.61
  • Support Level
  • INSM $194.65
  • ETR $92.74
  • Resistance Level
  • INSM $209.77
  • ETR $95.89
  • Average True Range (ATR)
  • INSM 6.85
  • ETR 1.68
  • MACD
  • INSM 0.15
  • ETR -0.06
  • Stochastic Oscillator
  • INSM 86.77
  • ETR 71.33

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About ETR Entergy Corporation

Entergy is a holding company with five regulated integrated utilities that generate and distribute electricity to about 3 million customers in Arkansas, Louisiana, Mississippi, and Texas. It is one of the largest power producers in the country with 24 gigawatts of rate-regulated owned and leased power generation capacity. Entergy was the second-largest nuclear owner in the US before it began retiring and selling its plants in the Northeast in 2014. It sold its two small gas utilities in Louisiana in 2025.

Share on Social Networks: